A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines

To join this study, you need to be an adult, aged 18 or older, and have received a diagnosis of psoriatic arthritis. Your psoriatic arthritis should have been active for at least three months, with a certain number of tender and swollen joints. You'll also need to have at least one active patch of psoriasis on your skin or changes to your nails typical of psoriasis.

The study is looking for people who haven't responded well to other common treatments for psoriatic arthritis. This could mean treatments like NSAIDs (painkillers), or standard disease-modifying drugs, or even up to two different biologic treatments.

However, you wouldn't be able to join if you have other conditions that might make it hard to tell if zasocitinib is working, such as rheumatoid arthritis, lupus, or gout. Also, if you have certain types of psoriasis that are not the ‘plaque’ type, or if your doctor thinks another skin condition might interfere with the study, you might not be suitable.

If you decide to take part, you'll be in the study for up to 60 weeks (about 14 months). During this time, you'll either receive the new drug, zasocitinib, or a placebo (a dummy drug). You won't know which one you're getting, and neither will your study doctor, until the study is over. You'll have regular visits to the clinic where doctors will assess your joints, skin, and overall health to see how you're responding. There will also be follow-up appointments to monitor your progress and safety. All instructions for taking the medication will be given to you by the study team.